For Q2, we expect a continued recovery of Bactiguard’s underlying business along with increased costs y/y and for the company to deliver on its growth strategy. Over the next couple of years, we expect Bactiguard to expand its underlying business (e.g. deeper penetration of its catheter portfolio and broader wound-care sales) and start to deliver on already secured licence partnerships as well as expanding into further collaborations.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.